Reported Dec 11, 2019 · Terminated
EXPAREL, Bupivicaine Liposome Injectable Suspension, 1.3%, 266 mg/20 mL (13 mg/mL), Sterile, 20 mL vial, Rx only,…
Pacira Pharmaceuticals, Inc.
Moderate riskThis product could cause temporary or reversible health problems — stop using it.What you should do
Stop using the affected lot and contact the recalling firm for the return or refund process. Check the FDA enforcement report for lot-level detail.
Firm contact: Pacira Pharmaceuticals, Inc. · 10450 Science Center Dr · San Diego, CA · 92121-1119
Is this the product you have?
- EXPAREL, Bupivicaine Liposome Injectable Suspension, 1.3%, 266 mg/20 mL (13 mg/mL), Sterile, 20 mL vial, Rx only
- Manufactured byPacira Pharmaceuticals, Inc. San Diego, CA 92121
- NDC65250-266-20
- Lot codes and dates
Pacira Lot #: 19-5002Patheon manufacturer Lot #: 098214Exp
- DateDec 2019
- Amount recalled
- 910 20 mL vials
Where it was sold
- Nationwide
Why it was recalled
Sub Potent Drug: Out of Specification (OOS)
This product could cause temporary or reversible health problems — stop using it.
Want the full recall guide?
The guide adds the identifying codes laid out for scanning, symptoms to watch for, a timeline, and news coverage of this recall.
Free recall alerts
Get alerted about new Pacira Pharmaceuticals, Inc. recalls
One email when a matching recall is published. No account, no cost, unsubscribe in one click.
We email you about recalls and nothing else. Every send has a one-click unsubscribe, and you can change your preferences any time without an account.